Prostate cancer trials in Germany

In Germany 95 Also abroad 1481

95 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Bergisch Gladbach, Berlin, Bonn, Dresden, Duisburg, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Herne, Mannheim, Mettmann, Muenster, Munich, Nuremberg, Rostock, Ulm
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duesseldorf, Duisburg, Essen, Giessen, Goettingen, Gronau (Westf.), Hamburg, Herne, Luebeck, Marburg, Muenster, Nuertingen, Nuremberg, Regensburg, Schwerin, Trier, Ulm, Wuerzburg
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Berlin, Duesseldorf, Goettingen, Hamburg, Heidelberg, Luebeck, Mettmann, Muenster, Nuertingen, Regensburg, Tuebingen, Ulm
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
Essen, Jena, Rostock, Tübingen
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Hamburg, Heidelberg, Jena, Ulm
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Duesseldorf, Jena
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
Phase 2Taking people
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
Where
Berlin, Essen, Heidelberg, Tuebingen
Age
18 years to 80 years
People
84
Run by
University Hospital Tuebingen
See details and how to joinNCT07860047 · EU 2025-522144-41-00
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Bayern, Berlin, Heidelberg, Mainz
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Essen, Jena
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Berlin, Essen, Hanover, München, Regensburg
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Essen, Munich
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena, Kiel, Ulm, Wuerzburg
Age
18 years and over
People
297 worldwide
Run by
Amgen Inc.
See details and how to join2025-520555-89-00 · EU 2025-520555-89-00
No phaseTaking people
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Where
Essen
Age
18 years and over
People
850 worldwide
Run by
XEOS Medical
See details and how to joinNCT06970275
No phaseTaking people
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Where
Homburg, Stuttgart
Age
18 years and over
People
132 worldwide
Run by
Varian, a Siemens Healthineers Company
See details and how to joinNCT05804318
Phase 3Taking people
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
Where
Dresden, Duesseldorf, Gronau (Westf.), Hamburg, Leipzig, Muenster, Munich, Rostock
Age
18 years and over
People
355 worldwide
Run by
Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
See details and how to join2023-504026-19-01 · EU 2023-504026-19-01
Phase 1Taking people
A study to test a new drug (TRP-001) given before prostate cancer surgery in patients with very high-risk Prostate cancer.”
Where
Cologne
Age
18 years and over
People
18
Run by
Torpedo Pharmaceuticals AG
See details and how to join2026-526406-32-00 · EU 2026-526406-32-00
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Heinsberg, Nuertingen
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1Taking people
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Essen, Heidelberg, Muenster, Munich
Age
18 years and over
People
479 worldwide
Run by
Amgen
See details and how to joinNCT04221542 · EU 2023-504361-23-00
No phaseEnrolling by invitation
RegisterPROS - A Registry for Prostate Cancers
Where
Münster
Age
45 years to 100 years
People
1,000
Run by
Wren Laboratories LLC
See details and how to joinNCT06872619
No phaseNot yet taking people in Germany
Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer
Where
Heidelberg
Age
18 years and over
People
54 worldwide
Run by
University of Zurich
See details and how to joinNCT07591051
Phase 1Taking people
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Where
Essen, Hamburg
Age
18 years to 64 years
People
40 worldwide
Run by
Amgen
See details and how to joinNCT06613100 · EU 2024-511965-13-00
Phase 2Taking people
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)
Where
Aachen, Augsburg, Duisburg, Freiburg im Breisgau, Muenster
Age
18 years and over
People
60
Run by
Universitaet Muenster
See details and how to join2025-521051-23-00 · EU 2025-521051-23-00
No phaseTaking people
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt (Oder), Fulda, Halle, Herford, Homburg, Jena, Konstanz, Leipzig, Ludwigshafen, Magdeburg, Mainz, Marburg, Munich, Nuremberg, Regensburg, Rostock, Stuttgart, Trier, Tübingen, Ulm, Würzburg
Age
18 years to 99 years
People
500
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06517719